The hyperkalemia treatment market is poised to register a CAGR of 16.79% over the forecast period.
The COVID-19 pandemic impacted the market significantly during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of COVID-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and COVID-19. For instance, according to an article published by PubMed in August 2021, there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. and concluded that there is a correlation between COVID-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the increasing prevalence of hyperkalemia, the rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market's growth. For instance, the article published by Healthline in March 2022 stated that high potassium levels, or hyperkalemia (HK), affect 40% to 50% of people with chronic kidney disease (CKD) globally, and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.
In addition, another article published by PubMed Central in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such disease prevalence is expected to necessitate the availability of drugs and diagnostics to the target population, contributing to the market's growth.
Therefore, owing to the above-mentioned factors, such as the increasing prevalence of hyperkalemia and the rising focus on research and development, the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder market growth over the forecast period.
According to the data updated by the National Kidney Foundation in 2022, it was shown that when HK develops abruptly and potassium levels become extremely high, patients can experience chest pain, nausea, vomiting, shortness of breath, and heart palpitations. Also, severe or chronic hyperkalemia can be a life-threatening condition that necessitates urgent medical attention for the patient's survival. Thus, the seriousness of the disease among the target population is expected to fuel the demand for drugs available for treatment, which is anticipated to drive market growth.
Furthermore, the research article published by PubMed in June 2021 mentioned that when a cohort study of 1,499 patients with cHK and CKD, heart failure, or diabetes mellitus was conducted with a 36-month follow-up,, the annual healthcare cost per patient with cHK was calculated to be double that of mild hyperkalemia. Hence, the burden of the condition requires more targeted drugs or therapies for treatment, which is further expected to drive segment growth.
As a result of factors such as the high prevalence of hyperkalemia, the segment is expected to grow during the analysis period.
As per the article published by PubMed in October 2021, HK contributes to nearly 800,000 emergency department visits annually in the United States, and the prevalence of the disease is growing owing to the aging population and the growth in associated comorbidities. Such a high burden of disease in the country is anticipated to demand the availability and development of advanced and effective drugs in the country. thereby driving the overall market growth in the region.
Furthermore, according to an article published by the Canadian Medical Association Journal in December 2021, in Canada, emergency department use is high among patients with CKD. Observational studies have associated hyperkalemia with increased hospital and intensive care unit admissions in Canada, and it was found that hyperkalemia accounts for 48% of all ambulatory care-sensitive conditions among patients on dialysis. Hence, the high burden of hyperkalemia in Canada is also expected to drive market growth.
In addition, the data updated by the CDC in February 2022 shows that in the United States, nearly 37 million adults are estimated to have CKD, and 40% of people who live with severely reduced kidney function are not aware of having CKD. Additionally, as per the source mentioned above, approximately 360 people begin dialysis treatment for kidney failure every 24 hours in the country. Thus, the burden of CKD is anticipated to increase the risk of hyperkalemia among the target population. This is expected to create urgent treatment options for the condition. which is further predicted to drive the market's growth over the analysis period.
Therefore, owing to the factors mentioned above, such as the increasing prevalence of hyperkalemia and chronic kidney disease, the market studied is anticipated to witness growth in the region.
This product will be delivered within 2 business days.
The COVID-19 pandemic impacted the market significantly during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of COVID-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and COVID-19. For instance, according to an article published by PubMed in August 2021, there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. and concluded that there is a correlation between COVID-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the increasing prevalence of hyperkalemia, the rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market's growth. For instance, the article published by Healthline in March 2022 stated that high potassium levels, or hyperkalemia (HK), affect 40% to 50% of people with chronic kidney disease (CKD) globally, and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.
In addition, another article published by PubMed Central in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such disease prevalence is expected to necessitate the availability of drugs and diagnostics to the target population, contributing to the market's growth.
Therefore, owing to the above-mentioned factors, such as the increasing prevalence of hyperkalemia and the rising focus on research and development, the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder market growth over the forecast period.
Hyperkalemia Treatment Market Trends
Chronic Hyperkalemia Segment is Anticipated to Witness Significant Growth Over the Forecast Period
Heart failure (HF) and chronic kidney disease (CKD) patients frequently have chronic hyperkalemia (cHK), a significant medical condition that can have detrimental effects and call for cautious management by cardiologists or nephrologists. Therefore, owing to the severity of the disease, the cHK segment is anticipated to witness growth over the forecast period.According to the data updated by the National Kidney Foundation in 2022, it was shown that when HK develops abruptly and potassium levels become extremely high, patients can experience chest pain, nausea, vomiting, shortness of breath, and heart palpitations. Also, severe or chronic hyperkalemia can be a life-threatening condition that necessitates urgent medical attention for the patient's survival. Thus, the seriousness of the disease among the target population is expected to fuel the demand for drugs available for treatment, which is anticipated to drive market growth.
Furthermore, the research article published by PubMed in June 2021 mentioned that when a cohort study of 1,499 patients with cHK and CKD, heart failure, or diabetes mellitus was conducted with a 36-month follow-up,, the annual healthcare cost per patient with cHK was calculated to be double that of mild hyperkalemia. Hence, the burden of the condition requires more targeted drugs or therapies for treatment, which is further expected to drive segment growth.
As a result of factors such as the high prevalence of hyperkalemia, the segment is expected to grow during the analysis period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to witness growth over the forecast period and have a significant market share. Among other countries in the region, the United States is leading the market due to factors such as an increase in healthcare expenditure, increasing research and developments, and the rising prevalence of hyperkalemia. As per the article published by PubMed in October 2021, HK contributes to nearly 800,000 emergency department visits annually in the United States, and the prevalence of the disease is growing owing to the aging population and the growth in associated comorbidities. Such a high burden of disease in the country is anticipated to demand the availability and development of advanced and effective drugs in the country. thereby driving the overall market growth in the region.
Furthermore, according to an article published by the Canadian Medical Association Journal in December 2021, in Canada, emergency department use is high among patients with CKD. Observational studies have associated hyperkalemia with increased hospital and intensive care unit admissions in Canada, and it was found that hyperkalemia accounts for 48% of all ambulatory care-sensitive conditions among patients on dialysis. Hence, the high burden of hyperkalemia in Canada is also expected to drive market growth.
In addition, the data updated by the CDC in February 2022 shows that in the United States, nearly 37 million adults are estimated to have CKD, and 40% of people who live with severely reduced kidney function are not aware of having CKD. Additionally, as per the source mentioned above, approximately 360 people begin dialysis treatment for kidney failure every 24 hours in the country. Thus, the burden of CKD is anticipated to increase the risk of hyperkalemia among the target population. This is expected to create urgent treatment options for the condition. which is further predicted to drive the market's growth over the analysis period.
Therefore, owing to the factors mentioned above, such as the increasing prevalence of hyperkalemia and chronic kidney disease, the market studied is anticipated to witness growth in the region.
Hyperkalemia Treatment Market Competitor Analysis
The hyperkalemia treatment market is consolidated globally and regionally and is dominated by a few players. A few key players in the market are AstraZeneca, Ardelyx, CSL Limited (Vifor Pharma Management Ltd.), Sanofi SA, and Perrigo Company PLC, among others.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Ardelyx
- Perrigo Company PLC
- Sanofi SA
- Odan Laboratories Ltd
- AdvaCare International
- Steadfast MediShield Pvt. Ltd.
- CSL Limited (Vifor Pharma Management Ltd.)
Methodology
LOADING...
